Select Bibliography

Filter by any of these (after searching):

O'Sullivan, Ciara C.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 2 items

Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)

Haddad, Tufia C. , He, Jun , O'Sullivan, Ciara C. , Chen, Beiyun ... - - Breast Cancer Res Treat - 2021

Manuscript - Primary - Primary - Breast - NCCTG-N0733

Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer (NCT04457596)

O'Sullivan, Ciara C. , Ballman, Karla V. , McCall, Linda ... - ASCO - J Clin Oncol - 2021

Abstract - No-Endpoint - Trial-Description-Only - Breast - Alliance-A011801